Hormones therapy for management of menopausal breast cancer risk

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Since the publication of the Women's Health Initiative, women seeking relief from menopausal symptoms often express concerns about the risk of hormone therapy (HT). In women at increased risk for breast cancer or with a personal history of breast cancer, the decision to use HT for the treatment of menopausal symptoms must be carefully considered in the context of the most recent literature. It is well established that HT is the most effective treatment for climacteric symptoms and sexual dysfunction. The evidence to date on the use of HT in women with a history of breast cancer is complicated by the fact that the majority of breast cancers are estrogen responsive and the concern about risk of recurrence. Over the past decade, survival after breast cancer treatment has continued to improve resulting in millions of survivors worldwide. As a result of breast cancer therapies, the prevalence of menopausal symptoms is increasing in survivors, and both clinicians and patients are seeking safe and effective therapies for symptom management. This article will review the role of HT in the treatment of menopausal symptoms in women without breast cancer and those with a personal history of breast cancer or those who are at increased risk of breast cancer. Management of menopause-related symptoms will be reviewed with a focus on strategies to improve quality of life.

Original languageEnglish (US)
Pages (from-to)223-230
Number of pages8
JournalMinerva Ginecologica
Volume64
Issue number3
StatePublished - Jun 2012

Fingerprint

Hormones
Breast Neoplasms
Therapeutics
Survivors
Women's Health
Menopause
Publications
Estrogens
Quality of Life
Recurrence
Survival

Keywords

  • Breast neoplasms
  • Hormone replacement therapy
  • Hot flashes
  • Menopause
  • Quality of life
  • Signs and symptoms
  • Survivor

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Hormones therapy for management of menopausal breast cancer risk. / Files, J. A.; Allen, Summer; Pruthi, Sandhya.

In: Minerva Ginecologica, Vol. 64, No. 3, 06.2012, p. 223-230.

Research output: Contribution to journalArticle

@article{a3952e0d6ab24026aa53d7dcac823379,
title = "Hormones therapy for management of menopausal breast cancer risk",
abstract = "Since the publication of the Women's Health Initiative, women seeking relief from menopausal symptoms often express concerns about the risk of hormone therapy (HT). In women at increased risk for breast cancer or with a personal history of breast cancer, the decision to use HT for the treatment of menopausal symptoms must be carefully considered in the context of the most recent literature. It is well established that HT is the most effective treatment for climacteric symptoms and sexual dysfunction. The evidence to date on the use of HT in women with a history of breast cancer is complicated by the fact that the majority of breast cancers are estrogen responsive and the concern about risk of recurrence. Over the past decade, survival after breast cancer treatment has continued to improve resulting in millions of survivors worldwide. As a result of breast cancer therapies, the prevalence of menopausal symptoms is increasing in survivors, and both clinicians and patients are seeking safe and effective therapies for symptom management. This article will review the role of HT in the treatment of menopausal symptoms in women without breast cancer and those with a personal history of breast cancer or those who are at increased risk of breast cancer. Management of menopause-related symptoms will be reviewed with a focus on strategies to improve quality of life.",
keywords = "Breast neoplasms, Hormone replacement therapy, Hot flashes, Menopause, Quality of life, Signs and symptoms, Survivor",
author = "Files, {J. A.} and Summer Allen and Sandhya Pruthi",
year = "2012",
month = "6",
language = "English (US)",
volume = "64",
pages = "223--230",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Hormones therapy for management of menopausal breast cancer risk

AU - Files, J. A.

AU - Allen, Summer

AU - Pruthi, Sandhya

PY - 2012/6

Y1 - 2012/6

N2 - Since the publication of the Women's Health Initiative, women seeking relief from menopausal symptoms often express concerns about the risk of hormone therapy (HT). In women at increased risk for breast cancer or with a personal history of breast cancer, the decision to use HT for the treatment of menopausal symptoms must be carefully considered in the context of the most recent literature. It is well established that HT is the most effective treatment for climacteric symptoms and sexual dysfunction. The evidence to date on the use of HT in women with a history of breast cancer is complicated by the fact that the majority of breast cancers are estrogen responsive and the concern about risk of recurrence. Over the past decade, survival after breast cancer treatment has continued to improve resulting in millions of survivors worldwide. As a result of breast cancer therapies, the prevalence of menopausal symptoms is increasing in survivors, and both clinicians and patients are seeking safe and effective therapies for symptom management. This article will review the role of HT in the treatment of menopausal symptoms in women without breast cancer and those with a personal history of breast cancer or those who are at increased risk of breast cancer. Management of menopause-related symptoms will be reviewed with a focus on strategies to improve quality of life.

AB - Since the publication of the Women's Health Initiative, women seeking relief from menopausal symptoms often express concerns about the risk of hormone therapy (HT). In women at increased risk for breast cancer or with a personal history of breast cancer, the decision to use HT for the treatment of menopausal symptoms must be carefully considered in the context of the most recent literature. It is well established that HT is the most effective treatment for climacteric symptoms and sexual dysfunction. The evidence to date on the use of HT in women with a history of breast cancer is complicated by the fact that the majority of breast cancers are estrogen responsive and the concern about risk of recurrence. Over the past decade, survival after breast cancer treatment has continued to improve resulting in millions of survivors worldwide. As a result of breast cancer therapies, the prevalence of menopausal symptoms is increasing in survivors, and both clinicians and patients are seeking safe and effective therapies for symptom management. This article will review the role of HT in the treatment of menopausal symptoms in women without breast cancer and those with a personal history of breast cancer or those who are at increased risk of breast cancer. Management of menopause-related symptoms will be reviewed with a focus on strategies to improve quality of life.

KW - Breast neoplasms

KW - Hormone replacement therapy

KW - Hot flashes

KW - Menopause

KW - Quality of life

KW - Signs and symptoms

KW - Survivor

UR - http://www.scopus.com/inward/record.url?scp=84864378621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864378621&partnerID=8YFLogxK

M3 - Article

C2 - 22635017

AN - SCOPUS:84864378621

VL - 64

SP - 223

EP - 230

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 3

ER -